IFNB1 and myeloid sarcoma: The patient was a 34-year-old woman with aggressive relapsing MS, previously treated with beta-interferon (stopped two years earlier), who received 120 mg of ALZ divided over five consecutive days, with no immediate side effects apart from a transient cutaneous rash.